Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 12, 2026

Enanta Pharmaceuticals Inc (ENTA)

A forensic read on Enanta Pharmaceuticals Inc built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

F · Poor — capital at risk

Forensic grade

Distress

Financial health

-1.2

Distress distance

Clean

Earnings quality

Forensic signals

-5.0

P / E (ttm)

-126.5%

ROE

$393M

Market cap

0.00%

Dividend yield

-3.4%

Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Enanta Pharmaceuticals Inc earns an F (Poor — capital at risk) forensic quality grade, and its balance-sheet distress test reads -1.2, placing it in the Distress zone. 2 forensic signals were flagged in its latest SEC filings, led by return on invested capital.

What the filings flag

-33.7%

FY2025

Return on invested capital. Return on invested capital is -33.7% in the latest fiscal year and steady — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.

+1.2%/yr

FY2022–FY2025

Share-count dilution. Diluted share count changed +4% over the last 3 years to FY2025 (+1.2%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. Note: the share count shows a large one-time jump around FY2014, consistent with a reverse split or bankruptcy reorg rather than gradual buybacks, so the earlier shrinkage doesn't reflect real repurchase discipline. That's ~1.2% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~3%.

Key fundamentals

Latest Revenue$65.3M

Revenue Growth YoY-3.4%

Revenue CAGR (3yr)-8.8%

Net Margin-125.4%

Free Cash Flow-$32.2M

Return on Equity-126.5%

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Enanta Pharmaceuticals Inc's actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Aug 12, 2026. Forensic signals flag probability, not certainty.